Spot Alert

The novel vaccine, from biopharma company GSK, is approved to prevent RSV-associated lower respiratory tract disease in adults aged ≥60 years.

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

Your daily dose of clinical news you may have missed.

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with incoming AAFP president Sterling Ransone, MD.

When combined, fluvoxamine and inhaled budesonide appear more likely than either agent alone to reduce risk of early COVID-19 becoming severe, say TOGETHER investigators.

The FDA action ends the use of monovalent COVID-19 mRNA vaccines from Pfizer/BioNTech and Moderna in favor of bivalent formulations to simplify the vaccination schedule, said the Agency.